Utama › Kanser Paru-paru Bukan Sel Kecil › Ohio › Akron
Kajian klinikal Kanser Paru-paru Bukan Sel Kecil di Akron, OH
22 kajian untuk Kanser Paru-paru Bukan Sel Kecil sedang mencari peserta di lokasi dalam dan sekitar Akron (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Mengambil pesertaFasa 3
- Cleveland Clinic Akron General, Akron
- Aultman Health Foundation, Canton · 21 mi jauh
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Mengambil pesertaFasa 3
- Aultman Health Foundation, Canton · 21 mi jauh
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Mengambil pesertaFasa 3
- Akron General Medical Center, Akron
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Mengambil pesertaFasa 3
- Aultman North, North Canton · 15 mi jauh
- Aultman Massillon, Massillon · 20 mi jauh
- Aultman Orrville Hospital, Orrville · 21 mi jauh
- dan 2 lagi
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Mengambil pesertaFasa 3
- Research Site, Canton · 21 mi jauh
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Mengambil pesertaFasa 3
- Aultman Hospital, Canton · 21 mi jauh
Pan-tumor MRD Study
Mengambil pesertaKajian pemerhatian
- Gabrail Cancer Center, Canton · 21 mi jauh
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Mengambil pesertaFasa 2/3
- Gabrail Cancer Center Research, Canton · 21 mi jauh
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
Mengambil pesertaFasa 2
- Gabrail Cancer Center, Canton · 21 mi jauh
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Mengambil pesertaFasa 2/3
- Tricounty Hematology and Oncology - Massillon, Massillon · 20 mi jauh
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
Mengambil pesertaFasa 1/2
- Gabrail Cancer Center Research, Canton · 21 mi jauh
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Mengambil pesertaFasa 3
- Gabrail Cancer Center, Canton · 21 mi jauh
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Mengambil pesertaFasa 2
- Gabrail Cancer and Research Center, Canton · 21 mi jauh
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Mengambil pesertaFasa 2
- Cleveland Clinic Mercy Hospital, Canton · 21 mi jauh
- Aultman Health Foundation, Canton · 21 mi jauh
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Mengambil pesertaFasa 2
- Aultman Health Foundation, Canton · 21 mi jauh
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Mengambil pesertaFasa 2
- Aultman Health Foundation, Canton · 21 mi jauh
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Mengambil pesertaFasa 2/3
- Aultman Health Foundation, Canton · 21 mi jauh
GEMINI-NSCLC: NSCLC Biomarker Study
Mengambil pesertaKajian pemerhatian
- Aultman Hospital, Canton · 21 mi jauh
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Mengambil pesertaFasa 1
- Gabrail Cancer & Research Center, Canton · 21 mi jauh
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Mengambil pesertaFasa 1/2
- Research Site 138, Canton · 21 mi jauh
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
Mengambil pesertaFasa 1/2
- Gabrail Cancer Center Research, Canton · 21 mi jauh
FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
Mengambil pesertaFasa 1/2
- Gabrail Cancer Research Center, Canton · 21 mi jauh
Kajian Kanser Paru-paru Bukan Sel Kecil di bandar lain
- Houston, TX145 kajian
- New York City, NY120 kajian
- Arlington, VA104 kajian
- Nashville, TN97 kajian
- Boston, MA90 kajian
- Los Angeles, CA87 kajian
- St. Louis, MO73 kajian
- Chicago, IL61 kajian
- Baltimore, MD60 kajian
- San Antonio, TX59 kajian
- Columbus, OH56 kajian
- Washington, DC55 kajian
Kajian lain di Akron
- Kanser Paru-paru16 kajian
- Kanser (semua jenis)13 kajian
- Kanser Payudara13 kajian
- Kanser Prostat9 kajian
- Leukemia Mieloid Akut8 kajian
- Melanoma8 kajian
- Kanser Paru-paru Sel Kecil8 kajian
- Kanser Metastatik8 kajian
- Kanser Kolorektal8 kajian
- Penyakit Hati Steatotik7 kajian
- Kanser Endometrium6 kajian
- Kanser Ovari6 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.